Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Regeneron Pharmaceuticals / Equity Bottom-Up

<ul><li>Regeneron Pharmaceuticals reported its third-quarter 2025 financial results, showcasing a mixed performance with both strong growth in some product lines and challenges in others.</li><li>The company's revenues reached $3.8 billion, marking a modest 1% increase from the previous year.</li><li>This growth was primarily driven by solid performances from several key products, including Dupixent, Libtayo, and EYLEA HD.</li></ul>

Regeneron Pharmaceuticals reported its third-quarter 2025 financial results, showcasing a mixed performance with both strong growth in some product lines and challenges in others.The company's revenues reached $3.8 billion, marking a modest 1% increase from the previous year.This growth was primarily driven by solid performances from several key products, including Dupixent, Libtayo, and EYLEA HD.

Regeneron Bets Big on U.S. Manufacturing – Can $7 Billion Transform Its Future?

Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Regeneron Pharmaceuticals  / Equity Bottom-Up

<ul>
  <li>Regeneron's growth is propelled by the strong performance of its blockbuster drugs, Eylea and Dupixent, alongside a promising and extensive late-stage pipeline, particularly in oncology and immunology.</li>
  <li>The company's proprietary VelociSuite® technology platform serves as a significant competitive advantage, enabling the rapid and efficient discovery and development of novel, fully human antibody-based therapies.</li>
  <li>Key challenges include heavy revenue concentration on Eylea and Dupixent, and the looming threat of biosimilar competition for Eylea, which could impact future revenue streams despite recent legal victories delaying entry.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Regeneron's growth is propelled by the strong performance of its blockbuster drugs, Eylea and Dupixent, alongside a promising and extensive late-stage pipeline, particularly in oncology and immunology.
  The company's proprietary VelociSuite® technology platform serves as a significant competitive advantage, enabling the rapid and efficient discovery and development of novel, fully human antibody-based therapies.
  Key challenges include heavy revenue concentration on Eylea and Dupixent, and the looming threat of biosimilar competition for Eylea, which could impact future revenue streams despite recent legal victories delaying entry.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Regeneron Pharmaceuticals  (REGN UW) - Sep 2025

<ul><li>Regeneron Pharmaceuticals presented a mixed performance for the second quarter of 2025, showcasing robust growth in certain product lines while facing challenges in others.</li><li>Overall, the company reported total revenues of $3.7 billion, marking a year-over-year increase of 4%, primarily buoyed by the impressive sales growth of flagship therapies like Dupixent and Libtayo, as well as the introduction and expansion of EYLEA HD.</li><li>However, the legacy EYLEA product witnessed a significant decline, with U.S. sales dropping 39% from the previous year due to competitive pressures and ongoing shifts toward EYLEA HD.</li></ul>

Regeneron Pharmaceuticals presented a mixed performance for the second quarter of 2025, showcasing robust growth in certain product lines while facing challenges in others.Overall, the company reported total revenues of $3.7 billion, marking a year-over-year increase of 4%, primarily buoyed by the impressive sales growth of flagship therapies like Dupixent and Libtayo, as well as the introduction and expansion of EYLEA HD.However, the legacy EYLEA product witnessed a significant decline, with U.S. sales dropping 39% from the previous year due to competitive pressures and ongoing shifts toward EYLEA HD.

Regeneron Pharmaceuticals: An Insight Into EYLEA Revenue and Market Dynamics!

<ul><li>Regeneron Pharmaceuticals' first quarter 2025 results illustrate a multifaceted performance landscape, marked by both promising advancements and significant hurdles across its drug portfolio.</li><li>Starting with EYLEA, the company saw U.S. net sales of $736 million, a decrease of 39% compared to the prior year, amid heightened competition from low-cost, off-label Avastin, influenced by patient affordability issues due to a funding gap at co-pay assistance foundations.</li><li>While EYLEA HD sales increased by 54% year-over-year, its sequential growth was stagnant.</li></ul>

Regeneron Pharmaceuticals' first quarter 2025 results illustrate a multifaceted performance landscape, marked by both promising advancements and significant hurdles across its drug portfolio.Starting with EYLEA, the company saw U.S. net sales of $736 million, a decrease of 39% compared to the prior year, amid heightened competition from low-cost, off-label Avastin, influenced by patient affordability issues due to a funding gap at co-pay assistance foundations.While EYLEA HD sales increased by 54% year-over-year, its sequential growth was stagnant.

Regeneron Pharmaceuticals: An Insight Into Dupixent's Market Presence & Recent Oncology Portfolio Expansion!

<ul><li>Regeneron Pharmaceuticals presented its fourth-quarter 2024 results, revealing a 10% year-over-year revenue growth, driven by strong performances from key product lines such as Dupixent, EYLEA, and Libtayo.</li><li>Dupixent, in particular, has become a blockbuster treatment in multiple indications, showing robust uptake across the globe with more than 1 million patients currently benefiting from the drug in various approved applications.</li><li>However, the performance of EYLEA was noted in a competitive landscape, with the company focused on increasing the market share of EYLEA HD through upcoming product enhancements like prefilled syringe options and extended dosing intervals.</li></ul>

Regeneron Pharmaceuticals presented its fourth-quarter 2024 results, revealing a 10% year-over-year revenue growth, driven by strong performances from key product lines such as Dupixent, EYLEA, and Libtayo.Dupixent, in particular, has become a blockbuster treatment in multiple indications, showing robust uptake across the globe with more than 1 million patients currently benefiting from the drug in various approved applications.However, the performance of EYLEA was noted in a competitive landscape, with the company focused on increasing the market share of EYLEA HD through upcoming product enhancements like prefilled syringe options and extended dosing intervals.

Regeneron Pharmaceuticals: Libtayo Expansion To Up Their Oncology Game!

United States

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. Regeneron Pharmaceuticals serves the healthcare sector in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Regeneron Pharmaceuticals (REGN UW)

Regeneron Bets Big on U.S. Manufacturing – Can $7 Billion Transform Its Future?

Regeneron Pharmaceuticals reported its third-quarter 2025 financial results, showcasing a mixed performance with both strong growth in some...

Baptista Research

Primer: Regeneron Pharmaceuticals (REGN UW) - Sep 2025

Regeneron's growth is propelled by the strong performance of its blockbuster drugs, Eylea and Dupixent, alongside a promising and extensive...

αSK

Regeneron Pharmaceuticals: An Insight Into EYLEA Revenue and Market Dynamics!

Regeneron Pharmaceuticals presented a mixed performance for the second quarter of 2025, showcasing robust growth in certain product lines while...

Baptista Research

Regeneron Pharmaceuticals: An Insight Into Dupixent's Market Presence & Recent Oncology Portfolio Expansion!

Regeneron Pharmaceuticals' first quarter 2025 results illustrate a multifaceted performance landscape, marked by both promising advancements and...

Baptista Research

Regeneron Pharmaceuticals: Libtayo Expansion To Up Their Oncology Game!

Regeneron Pharmaceuticals presented its fourth-quarter 2024 results, revealing a 10% year-over-year revenue growth, driven by strong performances...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)